Art. -Nr.: HY-153274

CWI1-2

6 Cited Publications

Kundenbewertung

Based on 6 publication(s) in Google Scholar

CWI1-2 is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.85%
CAS. Nr.: 2408590-36-1
Formel: C₂₂H₁₇Cl₃N₆O₃
Molecular Weight:519.77

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

CWI1-2 Chemical Structure

CAS. Nr.: 2408590-36-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (6)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
THP-1	IC₅₀	200 nM Compound: 12; CW11-2	Antiproliferative activity against human THP-1 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human THP-1 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay	[PMID: 38382391]

In Vitro

CWI1-2 (0-1 μM, 24 h) has good anti-leukemic efficacy^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:

MonoMac6, MOLM13
Concentration:

0-1 μM
Incubation Time:

24 h
Result:

Induced significant cell differentiation and apoptosis in a concentration-dependent manner in IGF2BP2-high cells but not in IGF2BP2-low cells.
Reduced Gln uptake and impaired mitochondrial function, resulting in reduced ATP production in AML cells.
Significantly inhibited the colony-forming ability of MA9-induced leukemic mouse blasts and greatly impairs the self-renewal of LSC/LIC.

In Vivo

CWI1-2 (5 mg/kg, i.v., once daily, 7-10 days) can significantly delay the onset of leukemia and prolong the survival time of BMT recipient B6.SJL (CD45.1) mice without any loss in body weight^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 2408590-36-1
Appearance Solid
Molecular Weight 519.77
Formel C₂₂H₁₇Cl₃N₆O₃
Color Light yellow to yellow
SMILES

OC(C=C1)=C(C=C1Cl)/C=N/N=C(N/N=C\C(C=C2Cl)=C(C=C2)O)\N/N=C/C(C=C3Cl)=C(C=C3)O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (6)

All Bio/Physico-chemical AssayWBCell Imaging/Staining

Sort by:

Journal Impact Factor

Nat Commun

Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m6A protein synthesis routes. [Abstract]

2025 Feb 7;16(1):1087. PMID: 39920115

CWI1-2 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 7;16(1):1087. [Abstract]

IGF2BP2 inhibitor CWI1-2 (1-5 μM) reduced HIV-1 luciferase expression in Vero E6 cells.
J Adv Res

PAD4-mediated citrullination of IGF2BP2 stabilizes MCM mRNAs to drive intrahepatic cholangiocarcinoma progression. [Abstract]

2026 Jun 5:S2090-1232(26)00460-1. PMID: 42250722
Int J Biol Sci

H3K27 Acetylation-driven IGF2BP2 Mutates during the Aging of MSCs, thereby Influencing Osteogenic Differentiation and Bone Aging. [Abstract]

2026 Jan 1;22(1):142-160. PMID: 41362747

CWI1-2 purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2026 Jan 1;22(1):142-160. [Abstract]

CWI1-2 (1 μM; 48 h) significantly reduced protein levels of HMGA1 in senescent MSCs.

CWI1-2 purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2026 Jan 1;22(1):142-160. [Abstract]

CWI1-2 (1 μM; 48 h) alleviated senescence in MSCs, as evidenced by reduced SA-β-gal positivity.

CWI1-2 purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2026 Jan 1;22(1):142-160. [Abstract]

CWI1-2 (1 μM; 48 h) reduced senescence marker expression in MSCs.

CWI1-2 purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2026 Jan 1;22(1):142-160. [Abstract]

CWI1-2 (1 μM; 48 h) decreased the fluorescence intensity of IGF2BP2 and Hmga1 mRNA and reduced their co-localization in MCSs.
Cell Rep

The m6A reader IGF2BP2 promotes homologous recombination-mediated DNA repair by eliminating DNA-RNA hybrids. [Abstract]

2025 Oct 15;44(10):116438. PMID: 41100254
Biochem Pharmacol

Chlorogenic acid promotes macrophage phagocytosis through the METTL3-SIRPA axis in an m6A-dependent manner for colon cancer therapy. [Abstract]

2026 Jun 25:252:118198. PMID: 42349614
SSRN

2025 Apr 10.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (192.39 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9239 mL

9.6196 mL

19.2393 mL

5 mM

0.3848 mL

1.9239 mL

3.8479 mL

10 mM

0.1924 mL

0.9620 mL

1.9239 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 1.25 mg/mL (2.40 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 1.25 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Hengyou Weng, et al. The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022 Dec 12;40(12):1566-1582.e10. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9239 mL	9.6196 mL	19.2393 mL	48.0982 mL
	5 mM	0.3848 mL	1.9239 mL	3.8479 mL	9.6196 mL
	10 mM	0.1924 mL	0.9620 mL	1.9239 mL	4.8098 mL
	15 mM	0.1283 mL	0.6413 mL	1.2826 mL	3.2065 mL
	20 mM	0.0962 mL	0.4810 mL	0.9620 mL	2.4049 mL
	25 mM	0.0770 mL	0.3848 mL	0.7696 mL	1.9239 mL
	30 mM	0.0641 mL	0.3207 mL	0.6413 mL	1.6033 mL
	40 mM	0.0481 mL	0.2405 mL	0.4810 mL	1.2025 mL
	50 mM	0.0385 mL	0.1924 mL	0.3848 mL	0.9620 mL
	60 mM	0.0321 mL	0.1603 mL	0.3207 mL	0.8016 mL
	80 mM	0.0240 mL	0.1202 mL	0.2405 mL	0.6012 mL
	100 mM	0.0192 mL	0.0962 mL	0.1924 mL	0.4810 mL

Keywords

CWI1-2

6 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

CWI1-2

Apoptosis Compound Library

Anti-Cancer Compound Library

Anti-Blood Cancer Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) CWI1-2

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

CWI1-2

Apoptosis Compound Library

Anti-Cancer Compound Library

Anti-Blood Cancer Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) CWI1-2

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

CWI1-2 Related Classifications

HY-153274 Related Classifications